CX 5461

Drug Profile

CX 5461

Alternative Names: CX-5461

Latest Information Update: 27 Jun 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cylene Pharmaceuticals
  • Developer BC Cancer Research Centre; Canadian Cancer Trials Group; Peter MacCallum Cancer Centre; Senhwa Biosciences
  • Class Amides; Antineoplastics; Heterocyclic compounds with 4 or more rings; Pyrazines; Small molecules; Thiazoles
  • Mechanism of Action RNA polymerase I inhibitors; Tumour suppressor protein p53 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Solid tumours
  • Phase I Haematological malignancies

Most Recent Events

  • 01 May 2016 Phase-I/II clinical trials in Solid tumours (Late-stage disease) in Canada (IV) (NCT02719977)
  • 16 Apr 2016 Preclinical trials in Solid tumours and Haematological malignancies in Canada before April 2016 (Intraperitoneal)
  • 16 Apr 2016 Pharmacodynamics and pharmacokinetics data from preclinical studies presented at the 107th Annual Meeting of the American Association for Cancer Research (AACR-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top